AlphAIAlphAI — Financial news for AI agents
rttnews.comOCT 281 min read$GMAB

Genmab Shares Surge 30% On Phase 3 Head And Neck Cancer Trial Data

Genmab's shares rose 30% to $58.15 after positive Phase 3 trial results for a head and neck cancer treatment. The stock opened at $44.64 and reached $57.60 during the session, with a 52-week range of $23.62 to $57.60.

Original reporting
rttnews.com
Published Oct 28, 2026, 3:52 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 5:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Genmab Shares Surge 30% On Phase 3 Head And Neck Cancer Trial Data — source image
Source · rttnews.com
Decision brief

The 30-second read

$GMABBullishHigh
01

Why it matters

The data represent a pivotal step toward FDA submission, prompting a 30% share surge and heightened investor interest in the company's pipeline.

02

Market read

The trial success is a high‑impact catalyst for Genmab and may influence related oncology stocks.

03

What to watch

Potential regulatory hurdles in the U.S. and competition from other head‑and‑neck therapies.

Relevance 9/10Novelty 9/10Timing: pre‑market today

Background

Genmab announced topline results from its global Phase 3 LiGeR-HN1 trial, showing efficacy in PD‑L1 positive recurrent/metastatic head and neck squamous cell carcinoma.

Company-level read

Ticker impact

$GMABBullishHigh confidence
Context

Genmab shares jumped 30% after reporting positive Phase 3 LiGeR-HN1 trial data for head and neck cancer.

Expected impact

likely upward pressure as investors price in regulatory approval potential

Evidence & confidence

Phase 3 success is a material catalyst for biotech stocks and the 30% intraday move confirms strong market reaction.

Market effects

Sector

May boost sentiment for other oncology biotech firms awaiting trial data.

Regional

European biotech sector could see a modest lift as Genmab is Denmark‑based.

Global

Positive trial results add to the broader narrative of advancing cancer therapies.

Counterpoint

What could challenge this read

If the trial data lack long‑term survival benefit, the rally could be short‑lived.

Key entities

  • company
    Genmab A/S

    Danish biotech firm developing antibody therapeutics.

Read at source← All news

StoryGenmab reports Phase 3 trial shows 50% death‑risk reduction for head‑and‑neck cancer combo

Also covered by

2 outlets

Related articles

OCT 28
$GMABHighAI 8/10

Biotech Stocks Rise: GMAB Surges, LUNG And AXGN Gain Over 30%

Genmab (GMAB) shares rose 33% after reporting positive Phase 3 results for its cancer drug. Pulmonx (LUNG) and Axogen (AXGN) shares gained over 30% on strong quarterly results. OrthoPediatrics (KIDS) and Replimune (REPL) also reported improved financials, driving their stock prices up. Specific financial data and guidance were provided by each company.

rttnews.com2 min
OCT 28
$GMABHigh

Genmab Stock (GMAB) Soars Over 30% on Strong Phase 3 Results for the Company’s Head and Neck Cancer Treatment

Genmab (GMAB) shares surged 30.54% after announcing positive Phase 3 trial results for petosemtamab combined with pembrolizumab in treating head and neck cancer. The treatment showed a 50% reduction in death risk. The company plans to seek regulatory approval. GMAB stock has gained 87.73% year-to-date and 54.3% over the past year. Analysts' average price target is $94.89, suggesting a 62.26% upside.

tipranks.com2 min
OCT 28
$GMABHigh

GMAB Stock Hits All-Time High After Genmab’s Cancer Drug Trial Meets Primary Goals — Here’s What Investors Need To Know

Genmab (GMAB) stock rose nearly 30% to an all-time high after positive Phase 3 trial results for its experimental head and neck cancer treatment, Petosemtamab, combined with Merck's Keytruda. The trial met primary goals, showing a 50% reduction in death risk and tripled tumor response odds. The company also reported positive Phase 3 results for its ovarian cancer drug, Rina-S, last week. Retail sentiment on Stocktwits turned bullish.

finance.yahoo.com2 min
OCT 28
$GMABHighAI 8/10

Genmab (GMAB) Stock Surges As Rina-S And Petosemtamab Data Fuel Bull Run

Genmab A/S (GMAB) stock surged 28.9% on October 28, 2026, following positive data for its oncology drugs Rina-S and petosemtamab. The company reported strong Phase 3 results for Rina-S in ovarian cancer and promising Phase 2 data for petosemtamab in colorectal and head and neck cancers. Analysts upgraded GMAB, citing the potential of these drugs, with JPMorgan raising its price target significantly. GMAB's revenue is approximately $21.53B, with a P/E ratio of 155.11.

timothysykes.com2 min
OCT 28
$GMABHighAI 9/10

Genmab reports 50% lower death risk in Phase 3 trial

Genmab reported that its petosemtamab combination reduced the risk of death by 50% in a Phase 3 head-and-neck cancer trial, meeting both primary endpoints. The study involved 699 patients. Genmab's shares rose 15.22% to $51.47 on Wednesday. The company plans to discuss results with global regulators.

mugglehead.com2 min